MacroGenics, Inc. (NASDAQ:MGNX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday.

According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “

A number of other equities research analysts also recently commented on the company. Stifel Nicolaus restated a “buy” rating and issued a $34.00 target price on shares of MacroGenics in a research report on Tuesday, September 12th. Cowen and Company reiterated a “buy” rating on shares of MacroGenics in a report on Friday, August 4th. ValuEngine cut MacroGenics from a “sell” rating to a “strong sell” rating in a report on Thursday, August 3rd. BidaskClub downgraded MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. Finally, Morgan Stanley cut their price objective on MacroGenics from $22.00 to $21.00 and set an “equal weight” rating for the company in a research report on Monday, August 7th. Four research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $30.30.

MacroGenics (MGNX) opened at 18.06 on Wednesday. The company has a 50-day moving average of $17.47 and a 200 day moving average of $18.20. The stock’s market cap is $664.57 million. MacroGenics has a 1-year low of $14.36 and a 1-year high of $31.85.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.09). The business had revenue of $1.70 million during the quarter, compared to analysts’ expectations of $15.82 million. MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The company’s revenue was down 97.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.12 earnings per share. Analysts predict that MacroGenics will post ($4.42) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/04/macrogenics-inc-mgnx-cut-to-sell-at-zacks-investment-research.html.

Several hedge funds have recently bought and sold shares of the stock. Interwest Venture Management Co. purchased a new position in MacroGenics during the 4th quarter valued at about $21,959,000. Wasatch Advisors Inc. lifted its position in shares of MacroGenics by 5,159.3% during the second quarter. Wasatch Advisors Inc. now owns 1,044,243 shares of the biopharmaceutical company’s stock worth $18,285,000 after purchasing an additional 1,024,388 shares in the last quarter. BB Biotech AG lifted its position in shares of MacroGenics by 179.8% during the third quarter. BB Biotech AG now owns 1,455,000 shares of the biopharmaceutical company’s stock worth $43,519,000 after purchasing an additional 935,000 shares in the last quarter. OppenheimerFunds Inc. lifted its position in shares of MacroGenics by 19.5% during the fourth quarter. OppenheimerFunds Inc. now owns 2,888,944 shares of the biopharmaceutical company’s stock worth $89,471,000 after purchasing an additional 472,320 shares in the last quarter. Finally, Baker BROS. Advisors LP acquired a new stake in shares of MacroGenics during the third quarter worth about $10,878,000. Hedge funds and other institutional investors own 84.47% of the company’s stock.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Get a free copy of the Zacks research report on MacroGenics (MGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.